3N 7540-00-634-4176 600-

HEALTH RECORD	CHRONOLOGICAL RECORD OF MEDICAL CARE								
DATE	SYMPTOMS, DIAGNOSIS, TREATMENT, TREATING ORGANIZATION (Sign each entry)								
FAN	MILY PRACTICE CL	INIC 31 ST MDG		AVIANO AB, ITALY		, ITALY			
High	igh Blood Pressure Initial Evaluation for adults >18 years of age per JNC VI.								
S:_	y/o M / F	F seen for initial evaluation of high blood pressure.							
Curr	ent symptoms:								
Prev	ious treatment: (includ	nt: (including meds, drugs, and herbal remedies, results and adverse affects)							
Rece	ent change in weight:								
Phys	sical Activity:								
Toba	acco:	ETO	H:						
Diet	: (Na,saturated fat,caffe	eine)							
Soci	al history: (family situa	ation,job,working	condition)			_			
PMF	H: CHD Heart Failure	CVA PVD Renal	Dz DM Dyslip	oidemia Go	out Sexual l	Dysfunction			
Fath	Father: HTN Early CHD CVA DM Dyslipidemia Renal Disease								
Motl	her: HTN Early CHD	CVA DM Dysl	ipidemia Renal	Disease					
Othe	er first degree relatives:								
ATIENT'S IDENTIFICATION (Laprint)	Jse this space for Mechanical	RECORDS MAINTAINED AT:							
		PATIENT'S NAME (Last, I	I First, Middle Initial)			SEX			
		RELATIONSHIP TO SPONSOR		STATUS		RANK/GRADE			
		SPONSOR'S NAME		ORGANIZATION					
		DEPART./SERVICE	SSN/IDENTIFICATION	NO.		DATE OF BIRTH			

General		O: P H	t Wt	BM	MI BF	<u> </u>	/	_	/_	(seated)
Neck Heart Lungs Abdomen Extremities Labs: UA CBC >		General-					/	_	/_	(standing)
Heart Lungs Abdomen Extremities Labs: UA CBC >		HEENT					/	_	/	(contralatera
Lungs Abdomen Extremities Labs: UA CBC >		Neck								
Abdomen Extremities Labs: UA CBC >		Heart								
Extremitics Labs: UA CBC >		Lungs								
Labs: UA CBC >		Abdomen								
Componets of CV risk stratification in patients with HTN Major Risk Factors Smoking Dyslipidemia DM Age>600 Sex (men and postmenopausal women) Family hx of CV disease women<65 Y or men <55 Y or men <		Extremities	S							
Componets of CV risk stratification in patients with HTN Major Risk Factors Smoking Dyslipidemia DM Age>60y Sex(men and postmenopausal women) Family hx of CV disease-women<65 y or men<65 y or men<65 y Target Organ Damage/Clinical CV Disease Heart Diseases LVII Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy PVD Retinopat		Labs: UA								
EKG		CBC :	><							
isk stratification in patients with HTN Major Risk Factors Smoking Dyslipidenia DM Age>60y Sex(men and postmenopausal women) Family kn of CV disease-women-65 yor men-55y Target Organ Damage Clinical CV Disease LVH Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy PVD Retinopathy Retinopathy Retinopathy Retinopathy Retinopathy PTO Stage 2&3 Drug therapy Stage 2 Drug therapy EKG Other A: Optimal BP Normal BP High-normal BP Stage HTN Isolated Systolic BP Pigh-normal BP Stage HTN Isolated Systolic BP Figh-normal BP Stage B Risk Gp S Stage S Risk Gp S Risk Gp B Risk Gp S At least 1 RF TOD/CCD and /or DM, with or without other RF No TOD/CCD High-normal Lifestyle modification Lifestyle modification Drug therapy Stage 2&3 Drug therapy Drug therapy Drug therapy Drug therapy Pour therapy Drug therapy Drug therapy Lifestyle modifications should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.		Chol	HDI	L						
Major Risk Factors Smoking Dyslipidenia DM Age>60y Sex(men and postmenopausal women) Family hx of CV disease.women<65 y or men<55y Target Organ Damage/Clinical CV Disease LVH Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy Retinopathy High-normal Lifestyle modification Find including DM Stage 2.83 Drug therapy Lifestyle modification Drug therapy Lifestyle modification Drug therapy Lifestyle modification Should be adjunctive therapy for all patients recommended for pharmacologic therapy. Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. Lifestyle modifications.	risk stratification in	EKG								
A: Optimal BP Normal BP High-normal BP Stage HTN Isolated Systolic BP Target Organ Damage Cardiac Risk Factors P: Drug Therapy: F/U: Target Organ Damage Cardiac Risk Factors P: Drug Therapy: F/U: P: Lifestyle modification P: Lifestyle modification P: Lifestyle modification Rain failure CVA or TIA Nephropathy PVD Retinopathy Retinopathy Risk Gp B Al least 1 RF ToDi/CCD and /or DM, with or without other RF No TODi/CCD High-normal BP High-normal BP High-normal BP Retinopathy Retinopathy Risk Gp B Al least 1 RF ToDi/CCD and /or DM, with or without other RF No TODI/CCD Retinopathy Risk Gp B Al least 1 RF ToDi/CCD and /or DM, with or without other RF No TODI/CCD Retinopathy Retinopath	Major Risk	Other								
Age>60y Sex(men and postmenopausal women) Family hx of CV disease:women<65 y or men<55y Target Organ Damage/Clinical CV Disease Heart Diseases LVH Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy P: Lifestyle modification Risk Stratification and Treatment BP Risk Gp A Risk Gp B Stages No RF: At least 1 RF TOD/CCD and /or DM, No TOD/CCD High-normal Lifestyle modification Risk Gp B Stages No RF: At least 1 RF TOD/CCD and /or DM, with or without other RF No TOD/CCD High-normal Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Lifestyle modification Drug therapy** Stage 2&3 Drug therapy Drug therapy Lifestyle modification Drug therapy Drug therapy Lifestyle modification Drug therapy Drug therapy Lifestyle modification Drug therapy Lifestyle modification bound be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.	Smoking Dyslipidemia DM	A: Optima	l BP Nor	mal BP	High-norn	nal BP	Stage_	HTN	Isolated S	ystolic BP
Sexmen and postmenopausal women) Family hx of CV disease:women-65y or men-55y Target Organ Damage/Clinical CV Disease Heart Diseases LVH Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy PUD Retinopathy PUD Retinopathy High-normal Lifestyle modification First Stratification and Treatment BP Risk Gp A Risk Gp B Stages No RF; At least 1 RF TOD/CCD and /or DM, No TOD/CCD not including DM with or without other RF No TOD/CCD High-normal Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Stage 1 Lifestyle modification Drug therapy* Lifestyle modification Drug therapy Lifestyle modification Drug therapy Lifestyle modification Drug therapy Lifestyle modification brug therapy Lifestyle modification Drug therapy Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.		Target Organ Damage								
Family hx of CV disease:women<65 y or men<55y Target Organ Damage/Clinical CV Disease Heart Diseases LVH Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy High-normal Lifestyle modification Fish Stratification and Treatment No TOD/CCD No TOD/CCD High-normal Lifestyle modification Stage 1 Lifestyle modification Stage 1 Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Drug therapy Toughterapy Toughterapy Toughterapy With or without other RF No TOD/CCD Lifestyle modification Drug therapy Toughterapy Toughtera	Sex(men and	Cardiac Risk Factors								
Target Organ Damage/Clinical CV Disease Heart Diseases LVH Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy High-normal Lifestyle modification Retinopathy High-normal Lifestyle modification Retinopathy Lifestyle modification Risk Gp B Stages No RF; At least 1 RF No TOD/CCD not including DM No TOD/CCD High-normal Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Lifestyle modification Drug therapy* Stage 2&3 Drug therapy Drug therapy Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.	Family hx of CV	P: Drug T	P: Drug Therapy:							
Heart Diseases LVH Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy PVD Retinopathy Edinopathy Retinopathy Retinopathy Lifestyle modification Risk Gp A Stages No RF; At least 1 RF No TOD/CCD No TOD/CCD No TOD/CCD High-normal Lifestyle modification Lifestyle modification Lifestyle modification Drug therapy** Stage 1 Lifestyle modification Lifestyle modification Drug therapy Lifestyle modification Drug therapy Lifestyle modification Drug therapy Lifestyle modification brug therapy Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.	y or men<55y									
Heart Diseases LVH Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy PVD Retinopathy High-normal Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Stage 2&3 Drug therapy Drug therapy Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.	Damage/Clinical									
Angina or prior MI Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy High-normal Lifestyle modification Etage 1 Lifestyle modification Pisk Stratification and Treatment BP Risk Gp A Risk Gp B Stages No RF; At least 1 RF No TOD/CCD not including DM with or without other RF No TOD/CCD High-normal Lifestyle modification Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Stage 2&3 Drug therapy Drug therapy Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.	Heart Diseases									
Prior coronary revascularization Heart failure CVA or TIA Nephropathy PVD Retinopathy High-normal Lifestyle modification Lifestyle modification Stage 1 Lifestyle modification Lifestyle modification Stage 2&3 Drug therapy Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications. **Risk Gp C** **Risk Gp C** **TOD/CCD and /or DM, **with or without other RF* **No TOD/CCD **Drug therapy** **Drug therapy** **Drug therapy** **Drug therapy* **Drug therapy* **For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.	Angina or prior	P: Lifesty	le modifica	tion						
CVA or TIA Nephropathy PVD Retinopathy Risk Gp A Risk Gp B Risk Gp C TOD/CCD and /or DM, with or without other RF No TOD/CCD High-normal Lifestyle modification Lifestyle modification Drug therapy** Stage 1 Lifestyle modification Lifestyle modification Drug therapy (up to 12 mo) (up to 6 mo)* Stage 2&3 Drug therapy Drug therapy Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.	Prior coronary revascularization									
High-normal Lifestyle modification Lifestyle modification Drug therapy** Stage 1 Lifestyle modification Lifestyle modification Drug therapy (up to 12 mo) (up to 6 mo)* Stage 2&3 Drug therapy Drug therapy Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.	CVA or TIA Nephropathy PVD	BP	Risk Gp A No RF;		At least 1 RF not including I	DM	TOD/C	CCD and /or		
Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.		Stage 1	Lifestyle me (up to 12 m	odifcation o)	Lifestyle modif Lifestyle modif (up to 6 mo)*	action	Drug th	nerapy		
		Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy. *For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.								
·										